Statin–Fibrate Combination Therapy

Shek, Allen; Ferrill, Mary J.

doi:10.1345/1542-6270(2001)035<0908:sfct>2.0.co;2

Cited by 25 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…83 As mentioned, myopathy is a potential concern when using this combination, but the risks can be attenuated by avoiding use in patients with renal impairment and appropriately monitoring patients and using moderate doses. 51,85 …”

Section: Statin/fibratementioning

confidence: 99%

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

Meagher¹

2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Background: There is a need to better diagnose and treat women who may be at risk for cardiovascular disease. This is emphasized by the impending release of evidence-based guidelines for the prevention of cardiovascular disease in women. Dyslipidemia is one of the most important modifiable risk factors for coronary heart disease (CHD) and is the focus of the current literature review.Methods: Medical literature on treating cardiovascular disease and cholesterol disorders in women was reviewed by searching Medline, including a selective search for randomized controlled clinical trials of lipid therapy. In addition, current dyslipidemia treatment guidelines were reviewed.Results and

show abstract

Section: Statin/fibratementioning

confidence: 99%

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

Meagher¹

2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

show abstract

“…Hypothyroidism is a known risk factor for the development of myopathy following statin (3-hydroxy-3-methyl glutaryl CoA reductase inhibitor) treatment (3)(4)(5)(6). Statins may lead to the development of de novo DM (7).…”

mentioning

confidence: 99%

Hypothyroidism Is a Risk Factor for New-Onset Diabetes: A Cohort Study

et al. 2015

View full text Add to dashboard Cite

OBJECTIVETo identify risk factors for the development of statin-associated diabetes mellitus (DM). RESEARCH DESIGN AND METHODSThe study was conducted in two phases. Phase one involved high-throughput in silico processing of a large amount of biomedical data to identify risk factors for the development of statin-associated DM. In phase two, the most prominent risk factor identified was confirmed in an observational cohort study at Clalit, the largest health care organization in Israel. Time-dependent Poisson regression multivariable models were performed to assess rate ratios (RRs) with 95% CIs for DM occurrence. RESULTSA total of 39,263 statin nonusers were matched by propensity score to 20,334 highly compliant statin initiators in [2004][2005] CONCLUSIONSHypothyroidism is a risk factor for DM. Subclinical hypothyroidism-associated risk for DM is prominent only upon statin use. Identifying and treating hypothyroidism and subclinical hypothyroidism might reduce DM risk. Future clinical studies are needed to confirm the findings.Thyroid disease is common in the general population. Hypothyroidism and subclinical hypothyroidism are more prevalent in patients with type 2 diabetes mellitus (DM), and it is possible that hypothyroidism is a risk factor for the development of DM. Women with subclinical hypothyroidism are more likely to develop gestational diabetes (1). After restoration of thyroid function, reduction of glucose-stimulated insulin secretion has been shown in patients with hypothyroidism as well as in those with subclinical hypothyroidism (2).

show abstract

“…Based on data obtained from epidemiological and clinical studies, the combination of any statin and fibrate increases the risk of myopathy usually in the first 12 weeks from the onset of therapy. The incidence of myotoxicity in combined statin-fibrate use is 0.12% [9]. Although the majority of reports on rhabdomyolysis includes gemfibrozil, some other fibrates (bezafibrate, clofibrate, fenofibrate) are also responsible for rhabdomyolysis cases when combined with statins [10].…”

Section: Discussionmentioning

confidence: 99%